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Cardiac protection by 
preoperative intervention in 
noncardiac surgery
ABSTRACT
Preoperative coronary intervention is one option to optimize the cardiac risk patient scheduled for noncardiac surgery. 
Such an intervention, however, is only justified for high risk procedures and if the indication for preoperative intervention is 
independent from surgery. 
Currently, PTCA with stent implantation is the most commonly used practice. Dependent of the type of stent (bare-metal 
stent or drug-eluting stent) dual antiplatelet therapy is mandatory for 1 – 12 months.
The surgeon, the cardiologist and the anesthesiologist have to decide in an interdisciplinary approach the perioperative 
management to navigate the patient between stent thrombosis and surgical bleeding.
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Coronary intervention may be one effec-
tive strategy to optimize the cardiac 
risk patient scheduled for noncardiac 
surgery (fig. 1). Available studies confirm 
a benefit of such an intervention if the 
indications for preoperative testing and 
intervention are independent from the 
surgical procedure (1, 2, 3). A net benefit 
of a preoperative intervention only exists if 
morbidity/mortality of noncardiac surgery 
without any pre-operative intervention (= 
immediate clearance for surgery) is ≥ 
morbidity/mortality of noncardiac surgery 
after extensive testing and intervention 
(fig. 2). Patients with low and intermediate 
risk procedures will not benefit.
Outcome of patients after prophylactic 
revascularization before noncardiac 
surgery seems not be different from 
patients with conservative management 
(4, 5). 
There has been a dramatic change in 
the landscape of coronary intervention 
in the last decade. Percutaneous 
coronary intervention dominates over 
coronary artery bypass graft surgery, 
and PTCA with coronary artery stenting 
is the preferred interventional strategy. 
Therefore, anesthesiologists are more 
Figure 1
Preoperative optimization of the coronary risk patient scheduled for 
noncardiac surgery
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and more confronted with patients 
after recent coronary artery stenting 
scheduled for noncardiac surgery. 
Coronary artery stenting implicates 
the need for dual antiplatelet drug 
therapy, usually with clopidogrel 
and aspirin. Discontinuation of dual 
antiplatelet drug therapy increases the 
risk of perioperative stent thrombosis 
and continuation of the risk of surgical 
bleeding. 
Kaluza et al reported an alarming 20% 
perioperative mortality rate (6). 
In 2003 Wilson et al published a 
retrospective study of 207 patients. 4% 
of them suffered from cardiac events 
inclusive of 6 patients, who died (7).
Recently, Vicenzi et al published a 
prospective outcome study enrolling 
all patients with a coronary artery 
stent within one year before NCS. 
44% suffered from complications after 
surgery, 4.9% died (8, fig. 3). All, but two 
(bleeding only) adverse events were of 
cardiac nature. The risk of suffering an 
event was 2.11 fold greater in patients 
with recent stents (< 35 days before 
surgery) as compared with PCI more 
than 90 days before surgery.
In the nonsurgical setting cardiologic 
trials documented greater bleeding 
risk when clopidogrel and aspirin were 
combined, compared to aspirin alone 
(9). Most of the surgical data comes from 
clinical studies in patients undergoing 
CABG-surgery (10, 11). Clopidogrel, a 
thienopyridin, inhibits platelet aggregation 
by irreversible blockade of adenosin 
diphosphat mediated platelet function. 
Normalization depends on the new 
platelet population. Most CABG-studies 
demonstrated that clopidogrel given 
within 4 to 5 days before CABG-surgery 
increased transfusion requirements and 
prolonged ICU-stay (10,11).
Recommended dual 
antiplatelet drug regime 
after stent implantation
The ACC/AHA Guidelines from 2002 
concluded that there is uncertainty 
regarding how much time should pass 
between PCI and NCS procedures. If 
a coronary stent is used, a delay of at 
least two weeks and ideally 4 to 6 weeks 
should occur before NCS to allow 4 full 
weeks of dual antiplatelet therapy and 
reendothelialization of the stent to be 
completed or nearly so (12).
The new Guidelines of the European 
Society of Cardiology for percutaneous 
coronary artery intervention recommend 
that after implantation of a bare metal 
stent clopidogrel must be continued for 
3 to 4 weeks and ASA lifelong, after drug-
eluting stents clopidogrel and ASA should 
be administered for 6 to 12 months to 
avoid late vessel thrombosis (13).
The new ACC/AHA 2005 Guideline 
update for percutaneous coronary 
intervention recommends that in 
patients who have undergone PCI, 
clopidogrel 75 mg daily should be given 
for at least 1 month after bare-metal 
stent implantation (unless the patient 
is at an increased risk for bleeding; 
then it should be given for a minimum 
of 2 weeks), 3 months after sirolimus 
stent implantation, and 6 months after 
paclitaxel stent implantation, and 
Figure 2
A net benefit of preoperative testing and intervention only exists 
if M/Ma > M/Mb+c+d+e 
Figure 3
Kaplan-Meier event time curve (combined coronary and bleeding events) of 
103 patients receiving a coronary artery stent within 1 year before noncardiac 
surgery (8).
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ideally up to 12 months in patients who 
are not at high risk of bleeding (level of 
evidence B) (14).
Perioperative management
Currently, many case reports and 
retrospective studies are available 
but no large prospective randomized 
trials. Therefore, we have to rely on 
recommendations of task forces and 
expert opinions (12-14). 
Basically, when assessing the peri-
operative risk of patients with recent 
coronary artery stenting before non-
cardiac surgery we have to plot the risk of 
thrombosis vs. the risk of bleeding (fig. 4). 
Dual antiplatelet regime can be stopped, 
changed or continued according to 
this assessment. Figure 4 shows the 
algorithm for preoperative management 
according to the urgency of noncardiac 
surgical procedures. Depending on the 
calculation of the thrombosis/bleeding 
risk 3 options are possible:
1. Continue clopidogrel + aspirin
e.g. peripheral vascular surgery can be 
performed under dual antiplatelet drug 
regime because vascular surgeons are 
familiar with such situations.
2. Continue aspirin, stop clopidogrel
This concept balances in many cases 
the risk benefit ratio
3. Stop clopidogrel, stop aspirin
This option should be strictly restricted 
to high bleeding procedures, like  
urologic, intracranial and some types 
or tumor surgery. 
Essentially, patients with recent coronary 
artery stents and dual antiplatelet therapy 
scheduled for noncardiac surgery benefit 
from a close collaboration between the 
surgeon, the anesthesiologist and the 
cardiologist. 
Figure 4
Algorithm for preoperative management of patients after PCI with dual 
antiplatelet drug therapy.
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